Ezetimibe patient counseling information: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Ezetimibe}} {{CMG}}; {{AE}} {{SS}} ==Patient Counseling Information== See FDA-Approved Patient Labeling (Patient Information). Patients should be advised to adh...")
 
(Redirected page to Ezetimibe)
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Ezetimibe]]
{{Ezetimibe}}
{{CMG}}; {{AE}} {{SS}}
 
==Patient Counseling Information==
 
See FDA-Approved Patient Labeling (Patient Information).
 
Patients should be advised to adhere to their National Cholesterol Education Program (NCEP)-recommended diet, a regular exercise program, and periodic testing of a fasting lipid panel.
 
===Muscle Pain===
 
All patients starting therapy with ezetimibe should be advised of the risk of [[myopathy ]]and told to report promptly any unexplained muscle pain, tenderness or weakness. The risk of this occurring is increased when taking certain types of medication. Patients should discuss all medication, both prescription and over-the-counter, with their physician.
 
===Liver Enzymes===
 
Liver tests should be performed when ZETIA is added to [[statin]] therapy and according to [[statin]] recommendations.
 
===Pregnancy===
 
Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using ZETIA added to [[statin]] therapy. Discuss future pregnancy plans with your patients, and discuss when to stop combination ZETIA and [[statin]] therapy if they are trying to conceive. Patients should be advised that if they become pregnant they should stop taking combination ZETIA and [[statin]] therapy and call their healthcare professional.
 
===Breastfeeding===
 
Women who are breastfeeding should be advised to not use ZETIA added to [[statin]] therapy. Patients who have a lipid disorder and are breastfeeding should be advised to discuss the options with their healthcare professionals.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ZETIA (EZETIMIBE) TABLET [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a773b0b2-d31c-4ff4-b9e8-1eb2d3a4d62a | publisher =  | date =  | accessdate = 11 February 2014 }}</ref>
 
==References==
 
{{Reflist|2}}
 
[[Category:Hypolipidemic agents]]
[[Category:Lactams]]
[[Category:Merck]]
[[Category:Schering-Plough]]
[[Category:Azetidines]]
[[Category:Organofluorides]]
[[Category:Phenols]]
[[Category:Cardiovasuclar Drugs]]
[[Category:Drugs]]

Latest revision as of 14:18, 21 July 2014

Redirect to: